Press Releases
TxCell to present an innovative, personalized cell-based immunotherapy approach at Biotech Showcase™ 2014, San Francisco, USA
TxCell SA, a clinical stage biotechnology company developing innovative, personalized cell-based immunotherapies using antigen-specific regulatory T-cells (Ag-Tregs) for chronic inflammatory and autoimmune diseases, announces today...
Press Releases
Adocia launches phase IIa clinical trial for its ultra-fast acting formulation of analog insulin
Adocia , a biotechnology company specialized in the development of ‘best-in-class’ medicines from already approved therapeutic proteins, in particular proteins and oncologic treatments, launches today...
Press Releases
Domain Therapeutics, Universite de Montreal, IRICoR and McGill University sign new licensing and partnership agreement on G-Protein Coupled Receptor biosensor technology
Domain Therapeutics, a France-based biopharmaceutical company that specializes in the research and development of new drug candidates that target G-protein coupled receptors (GPCRs), is pleased...
Press Releases
Biosimilars & Biobetters USA – Industry leaders will meet in Iselin, New Jersey, in April 2014
Creating an Innovate Plan for the USA Biosimilars Market: presentations from Sandoz, IMS Health, Bristows, PRA International, Celltrion, MedImmune, Novartis, Lonza Biologics and others. ...
Press Releases
Eureka Science proudly announces the collaboration with international societies & organizations for their events “6th International Conference on Drug Discovery” and “Therapy and 3rd...
Eureka Science proudly announces the collaboration with international societies and organizations for the events; the “6th International Conference on Drug Discovery and Therapy” and the...
Press Releases
FibroGen Announces Analysis of Peritoneal Dialysis Patients With Chronic Kidney Disease From Roxadustat (FG-4592) Incident Dialysis Study
FibroGen Inc. (FibroGen) today announced the presentation of a Phase 2 subgroup analysis comparing treatment response to roxadustat (FG-4592) a first-in-class oral compound in late...
Press Releases
Oncodesign and UCB enter into a research collaboration for the early development of new therapeutic agents in neurodegenerative diseases
The partnership is based on Oncodesign's Nanocyclix(R) technology platform for next generation kinase inhibitors and UCB’s expertise in neurology. Oncodesign, a...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.